[go: up one dir, main page]

BRPI0810631A2 - métodos para detecção de dano cardíaco - Google Patents

métodos para detecção de dano cardíaco

Info

Publication number
BRPI0810631A2
BRPI0810631A2 BRPI0810631A BRPI0810631A BRPI0810631A2 BR PI0810631 A2 BRPI0810631 A2 BR PI0810631A2 BR PI0810631 A BRPI0810631 A BR PI0810631A BR PI0810631 A BRPI0810631 A BR PI0810631A BR PI0810631 A2 BRPI0810631 A2 BR PI0810631A2
Authority
BR
Brazil
Prior art keywords
methods
damage detection
cardiac damage
cardiac
detection
Prior art date
Application number
BRPI0810631A
Other languages
English (en)
Inventor
O Caggiano Anthony
Yan Xinhua
Original Assignee
Acorda Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Acorda Therapeutics Inc filed Critical Acorda Therapeutics Inc
Publication of BRPI0810631A2 publication Critical patent/BRPI0810631A2/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18Growth factors; Growth regulators
    • A61K38/1883Neuregulins, e.g.. p185erbB2 ligands, glial growth factor, heregulin, ARIA, neu differentiation factor
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5061Muscle cells
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00Preparations for testing in vivo
    • A61K49/0004Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/04Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5091Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing the pathological state of an organism
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6887Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids from muscle, cartilage or connective tissue
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47Assays involving proteins of known structure or function as defined in the subgroups
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701Details
    • G01N2333/4712Muscle proteins, e.g. myosin, actin, protein
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/32Cardiovascular disorders
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/32Cardiovascular disorders
    • G01N2800/324Coronary artery diseases, e.g. angina pectoris, myocardial infarction

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • General Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pathology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cardiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Toxicology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Physiology (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
BRPI0810631A 2007-05-10 2008-05-12 métodos para detecção de dano cardíaco BRPI0810631A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US92854107P 2007-05-10 2007-05-10
PCT/US2008/006060 WO2008140814A1 (en) 2007-05-10 2008-05-12 Methods for detecting cardiac damage

Publications (1)

Publication Number Publication Date
BRPI0810631A2 true BRPI0810631A2 (pt) 2017-05-09

Family

ID=40002559

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0810631A BRPI0810631A2 (pt) 2007-05-10 2008-05-12 métodos para detecção de dano cardíaco

Country Status (11)

Country Link
US (5) US8628929B2 (pt)
EP (1) EP2153228A4 (pt)
JP (5) JP5749490B2 (pt)
CN (2) CN101743474B (pt)
AU (1) AU2008251822B2 (pt)
BR (1) BRPI0810631A2 (pt)
CA (2) CA2965208C (pt)
IN (1) IN2014MN01227A (pt)
MX (2) MX2009012174A (pt)
RU (1) RU2498309C2 (pt)
WO (1) WO2008140814A1 (pt)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2008251822B2 (en) 2007-05-10 2014-02-06 Acorda Therapeutics, Inc. Methods for detecting cardiac damage
RU2501564C2 (ru) 2008-08-15 2013-12-20 Акорда Терапьютикс, Инк. Композиции и способы для лечения во время не острых периодов после неврологического повреждения цнс
US9198952B2 (en) 2008-09-22 2015-12-01 The Brigham And Women's Hospital, Inc. Compositions of and methods of using ligand dimers
JP5743898B2 (ja) 2008-11-28 2015-07-01 ゼンサン (シャンハイ) サイエンス アンド テクノロジー リミテッド ニューレグリンペプチド及びその使用
US8652788B2 (en) * 2009-12-02 2014-02-18 Abbott Laboratories Assay for diagnosis of cardiac myocyte damage
US8835120B2 (en) * 2009-12-02 2014-09-16 Abbott Laboratories Assay for cardiac troponin-T (cTnT)
WO2011119836A1 (en) * 2010-03-24 2011-09-29 Massachusetts Institute Of Technology Methods and compositions for cardioprotection and cardioregeneration
EP2609427B1 (en) * 2010-08-26 2015-01-21 Roche Diagnostics GmbH Use of biomarkers in the assessment of the early transition from arterial hypertension to heart failure
BR112017005730B1 (pt) 2014-09-26 2023-12-12 Somalogic Operating Co., Inc Método para triagem de um indivíduo quanto ao risco de um evento cardiovascular ou para predizer a probabilidade que um indivíduo tenha tal evento
RU2585391C1 (ru) * 2014-12-19 2016-05-27 Федеральное государственное бюджетное образовательное учреждение высшего профессионального образования Чеченский государственный университет Способ иммунологического прогнозирования малых повреждений миокарда
US20180296642A1 (en) * 2015-09-25 2018-10-18 Douglas B. Sawyer Methods for treating cardiac injury
RU2648529C1 (ru) * 2016-12-27 2018-03-26 Федеральное государственное бюджетное образовательное учреждение высшего образования "Астраханский государственный медицинский университет" Министерства здравоохранения Российской Федерации (ФГБОУ ВО Астраханский ГМУ Минздрава России) Способ оценки эффективности лекарственной терапии у взрослых пациентов с острой сердечной недостаточностью после операций на открытом сердце, получающих лечение методом экстракорпоральной мембранной оксигенации
RU2709458C2 (ru) * 2017-12-22 2019-12-18 Марина Александровна Чичкова Способ оптимизации ранней иммунологической диагностики осложнений чрескожного коронарного вмешательства у пациентов с ИБС
RU2722111C1 (ru) * 2019-12-30 2020-05-26 Федеральное государственное бюджетное образовательное учреждение высшего образования "Самарский государственный медицинский университет" Министерства здравоохранения Российской Федерации Способ ведения пациентов с хроническим лимфолейкозом в процессе полихимиотерапии по схеме fcr, направленный на предотвращение кардиотоксичности
RU2749552C1 (ru) * 2020-08-03 2021-06-15 Федеральное государственное бюджетное научное учреждение "Томский национальный исследовательский медицинский центр Российской академии наук" (Томский НИМЦ) Способ отбора пациентов с длительно персистирующей формой фибрилляции предсердий на проведение эффективного катетерного лечения
RU2760242C1 (ru) * 2021-03-01 2021-11-23 федеральное государственное бюджетное учреждение "Национальный медицинский исследовательский центр имени В.А. Алмазова" Министерства здравоохранения Российской Федерации Способ оценки повреждения миокарда и риска развития осложнений после операций на сердце в условиях искусственного кровообращения
CN113238060B (zh) * 2021-05-08 2022-10-11 迈克生物股份有限公司 用于预测或诊断心肌炎的试剂盒

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7115554B1 (en) 1993-05-06 2006-10-03 Acorda Therapeutics, Inc. Methods of increasing myotube formation or survival or muscle cell mitogenesis differentiation or survival using neuregulin GGF III
US5716930A (en) 1991-04-10 1998-02-10 Ludwig Institute For Cancer Research Glial growth factors
US5530109A (en) * 1991-04-10 1996-06-25 Ludwig Institute For Cancer Research DNA encoding glial mitogenic factors
US5324502A (en) * 1992-04-02 1994-06-28 Purdue Research Foundation Radiopharmaceuticals for imaging the heart
US6092695A (en) 1992-05-11 2000-07-25 Cytologix Corporation Interchangeable liquid dispensing cartridge pump
US6635249B1 (en) * 1999-04-23 2003-10-21 Cenes Pharmaceuticals, Inc. Methods for treating congestive heart failure
US6653249B1 (en) * 2000-05-25 2003-11-25 Penn Emblem Corporation Emblem having calendered fabric layer
GB0029154D0 (en) * 2000-11-30 2001-01-17 Lee Helen Signal enhancement with multiple labelled-antibodies
AU2002304965A1 (en) * 2002-05-24 2003-12-12 Zensun (Shanghai) Sci-Tech.Ltd Neuregulin based methods and compositions for treating viral myocarditis and dilated cardiomyopathy
CN1267590C (zh) * 2004-06-11 2006-08-02 清华大学 一种用于组织修复的生长因子缓释体系的制备方法
CN1715926B (zh) * 2004-07-02 2011-08-17 上海泽生科技开发有限公司 神经调节蛋白突变体的应用
EP1901764A1 (en) 2005-07-14 2008-03-26 Myogen, Inc. Use of inhibitors of the ubiquitin proteasome pathway for increasing contractility of the heart
WO2007028085A2 (en) * 2005-09-02 2007-03-08 Morehouse School Of Medicine Neuregulin for prevention and treatment of damage from acute assault on vascular and neuronal tissues
AU2008251822B2 (en) 2007-05-10 2014-02-06 Acorda Therapeutics, Inc. Methods for detecting cardiac damage
DE102007061117A1 (de) 2007-12-19 2009-06-25 Robert Bosch Gmbh Elektrische Kontaktierung
CA2845198A1 (en) 2010-08-13 2012-02-16 Georgetown University Ggf2 and methods of use

Also Published As

Publication number Publication date
CA2686959C (en) 2017-06-13
WO2008140814A1 (en) 2008-11-20
JP5749490B2 (ja) 2015-07-15
US10258667B2 (en) 2019-04-16
CN104614510B (zh) 2017-07-04
CN101743474A (zh) 2010-06-16
CA2965208A1 (en) 2008-11-20
CN104614510A (zh) 2015-05-13
JP2010527000A (ja) 2010-08-05
US9757429B2 (en) 2017-09-12
MX2009012174A (es) 2010-03-30
RU2498309C2 (ru) 2013-11-10
US20110085976A1 (en) 2011-04-14
EP2153228A1 (en) 2010-02-17
US20190269759A1 (en) 2019-09-05
US11071770B2 (en) 2021-07-27
JP6636402B2 (ja) 2020-01-29
US8628929B2 (en) 2014-01-14
JP2017026622A (ja) 2017-02-02
CN101743474B (zh) 2015-06-03
US9329171B2 (en) 2016-05-03
MX348082B (es) 2017-05-25
CA2965208C (en) 2022-06-14
AU2008251822B2 (en) 2014-02-06
RU2009145695A (ru) 2011-06-20
US20140378377A1 (en) 2014-12-25
JP6978553B2 (ja) 2021-12-08
US20180028610A1 (en) 2018-02-01
JP5998171B2 (ja) 2016-09-28
CA2686959A1 (en) 2008-11-20
AU2008251822A1 (en) 2008-11-20
IN2014MN01227A (pt) 2015-07-03
JP2014122923A (ja) 2014-07-03
US20160263192A1 (en) 2016-09-15
JP2019010123A (ja) 2019-01-24
JP2020176138A (ja) 2020-10-29
EP2153228A4 (en) 2010-08-04

Similar Documents

Publication Publication Date Title
BRPI0810631A2 (pt) métodos para detecção de dano cardíaco
BRPI0814359A2 (pt) Método
BRPI0817226A2 (pt) Método
BRPI0817726A2 (pt) Método
BRPI0806898A2 (pt) Inibidores de mek
DE112009004699A5 (de) Elektrochirurgisches System
BRPI0919116A2 (pt) método
EP4024013C0 (en) ANALYSIS SYSTEM
DK2308877T3 (da) Imidazopyridin-2-on-derivater
DK3351326T3 (da) Rilleforarbejdningsfremgangsmåde
NO20085322L (no) Fremgangsmate for raskere ansiktsdeteksjon
BR112012004593A2 (pt) "método"
DK2313489T3 (da) Fremstillingsmetode
FR2959903B1 (fr) Procede d'imagerie polychrome
DK2275414T3 (da) Cyclopentylacrylamidderivat
DK2155273T3 (da) Lugtregulerende genstand
BRPI0911625A2 (pt) Métodos
DE602008004490D1 (de) Werkzeugwechselsystem
BRPI0911359A2 (pt) híbridos polímero - dendrímero
BRPI0809678A2 (pt) Métodos
DE502008001622D1 (de) Lagereinrichtung
ATE534634T1 (de) 2-phenyl-4-cyclopropyl-pyrimidinderivate
BRPI0810416A2 (pt) Método de hidroformação
NO20073343L (no) Detektorsystem
DK2147106T3 (da) Expressionssystem

Legal Events

Date Code Title Description
B15K Others concerning applications: alteration of classification

Ipc: A61K 38/18 (2006.01), A61K 49/00 (2006.01), G01N 3

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B12B Appeal against refusal [chapter 12.2 patent gazette]
B25G Requested change of headquarter approved

Owner name: ACORDA THERAPEUTICS, INC. (US)

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 16A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2775 DE 12-03-2024 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.